Trichostatin A (TSA)

Name: Trichostatin A (TSA)
Brand: Selleck Chemicals
SKU: S1045
Rating: 5 (185 reviews)

For research use only.

Catalog No.S1045

185 publications

CAS No. 58880-19-6

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Selleck's Trichostatin A (TSA) has been cited by 185 publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2017, 171(4):824-835.e18

PubMed: 29056338 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cancer Cell, 2014, 26(4):534-48

PubMed: 25314079 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00051-4

PubMed: 33651988 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(22)e2014681118

PubMed: 34035164 ( click the link to review the publication )

Theranostics, 2021, 11(8):3760-3780

PubMed: 33664860 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108646

PubMed: 33472062 ( click the link to review the publication )

Cancer Lett, 2021, 513:36-49

PubMed: 33991616 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5657

PubMed: 33638154 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):532

PubMed: 34031358 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):405

PubMed: 33854041 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Mol Cell Biochem, 2021, 10.1007/s11010-021-04050-3

PubMed: 33515198 ( click the link to review the publication )

Nat Metab, 2021, 3(1):75-89

PubMed: 33462516 ( click the link to review the publication )

Sci Adv, 2021, 7(9)eabe5518

PubMed: 33627431 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108646

PubMed: 33472062 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2019.1709762

PubMed: 31986961 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )
Cell Rep, 2020, 33(11):108507

PubMed: 33326790 ( click the link to review the publication )

mBio, 2020, 11(5)e02343-20

PubMed: 33024042 ( click the link to review the publication )

Free Radic Biol Med, 2020, 10.1016/j.freeradbiomed.2020.01.016

PubMed: 31972340 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Front Immunol, 2020, 3;11:36

PubMed: 32117228 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.0417.2020

PubMed: 33277442 ( click the link to review the publication )

Mol Neurobiol, 2020, 10.1007/s12035-019-01812-5

PubMed: 31919777 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Cancer Biol Med, 2020, 17(4):953-969

PubMed: 33299646 ( click the link to review the publication )

Immunol Cell Biol, 2020, 98(4):318-331

PubMed: 31950542 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

J Immunol Res, 2020, 2020:7263602

PubMed: 33062724 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

Arch Insect Biochem Physiol, 2020, 103(4):e21649

PubMed: 31777104 ( click the link to review the publication )

Cell Rep, 2020, 30(7):2195-2208

PubMed: 32075759 ( click the link to review the publication )

Theranostics, 2020, 10(17):7747-7757

PubMed: 32685017 ( click the link to review the publication )

Theranostics, 2020, 10(5):2188-2200

PubMed: 32104503 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Mol Cell, 2019, 74(6):1250-1263

PubMed: 31054974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5792

PubMed: 31857589 ( click the link to review the publication )
Nat Commun, 2019, 10(1):4353

PubMed: 31554795 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5800

PubMed: 31863007 ( click the link to review the publication )

Nucleic Acids Res, 2019, 19;47(16):8502-8520

PubMed: 31616951 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1707488

PubMed: 31878840 ( click the link to review the publication )

PLoS Biol, 2019, 17(10):e3000461

PubMed: 31600191 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

J Cell Biol, 2019, 218(1):267-284

PubMed: 30538141 ( click the link to review the publication )

J Cell Biol, 2019, 218(12):4017-4029

PubMed: 31645458 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32425

PubMed: 31111958 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

EBioMedicine, 2019, 43:238-252

PubMed: 31047858 ( click the link to review the publication )

J Bone Miner Res, 2019, 10.1002/jbmr.3716

PubMed: 31112333 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):428

PubMed: 31665064 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):84

PubMed: 30777099 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz093

PubMed: 31560394 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(4):541-552

PubMed: 30806715 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3442-3452

PubMed: 31432592 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )
J Virol, 2019, 93(4)e01896-18

PubMed: 30518648 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4360

PubMed: 30867438 ( click the link to review the publication )

PLoS Comput Biol, 2019, 15(2):e1006826

PubMed: 30785874 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 223:1-8

PubMed: 30862568 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29470

PubMed: 31692090 ( click the link to review the publication )

Cell Adh Migr, 2019, 13(1):285-292

PubMed: 31271097 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(5):822-832

PubMed: 30860602 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3209-3218

PubMed: 31002353 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):285-293

PubMed: 30387821 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Reprod Fertil Dev, 2019, 31(3):473-481

PubMed: 30301509 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

bioRxiv, 2019, 10.1101/748129

PubMed: N/A ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4098-4114

PubMed: 30124467 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )
Mol Ther, 2018, 26(7):1828-1839

PubMed: 29730197 ( click the link to review the publication )

Oncogene, 2018, 37(8):1049-1061

PubMed: 29084211 ( click the link to review the publication )

Oncogene, 2018, 37(50):6414-6424

PubMed: 30068939 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Mol Oncol, 2018, 12(5):724-755

PubMed: 29577611 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Plant Cell Rep, 2018, 37(1):115-123

PubMed: 28939922 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Int Immunopharmacol, 2018, 65:303-311

PubMed: 30342347 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 503(2):420-427

PubMed: 29649477 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Med Sci Monit, 2018, 24:461-472

PubMed: 29363667 ( click the link to review the publication )

Methods Mol Biol, 2018, 1755:179-195

PubMed: 29671271 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Cell Res, 2017, 27(7):898-915

PubMed: 28497810 ( click the link to review the publication )

Mol Cell, 2017, 67(4):566-578

PubMed: 28803781 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Plant Physiol, 2017, 175(3):1484-1496

PubMed: 28972079 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )
Cancer Epidemiol Biomarkers Prev, 2017, 26(9):1411-1419

PubMed: 28619831 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Sci Rep, 2017, 7:46195

PubMed: 28387374 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

J Diabetes Res, 2017, 2017:8208065

PubMed: 28191472 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):51-60

PubMed: 28110187 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 485(2):454-460

PubMed: 28192116 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1978-88

PubMed: 26634271 ( click the link to review the publication )

Thorax, 2016, 633-45

PubMed: 27071418 ( click the link to review the publication )

EMBO Rep, 2016, 17(7):999-1012

PubMed: 27154402 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Free Radic Biol Med, 2016, 99:167-178

PubMed: 27498117 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:4085727

PubMed: 27746856 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )
Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Int J Oncol, 2016, 48(6):2591-607

PubMed: 27082124 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):886

PubMed: 27842508 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8293-304

PubMed: 26729194 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1586

PubMed: 25569103 ( click the link to review the publication )

J Antimicrob Chemother, 2015, 10.1093/jac/dku549

PubMed: 25558076 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: 25303559 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

Chem Biol Interact, 2015, 242:227-34

PubMed: 26482938 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120587

PubMed: 25807249 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EMBO J, 2014, 34(1):115-29

PubMed: 25398909 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )
PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Development, 2014, 141(7):1534-43

PubMed: 24598165 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-16

PubMed: 24200994 ( click the link to review the publication )

Life Sci, 2014, 99(1-2):31-6

PubMed: 24486299 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):574-80

PubMed: 24607957 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6701-15

PubMed: 25149533 ( click the link to review the publication )

Sci Rep, 2014, 4:4663

PubMed: 24722541 ( click the link to review the publication )

Science, 2014, 344(6183):1252304

PubMed: 24727982 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Plant J, 2013, 74(5):815-28

PubMed: 23464703 ( click the link to review the publication )

Cytokine, 2013, 65(2):121-5

PubMed: 24373940 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Epigenetics, 2012, 7(10):1161-72

PubMed: 22965008 ( click the link to review the publication )

Adv Genet, 2010, 70:341-86

PubMed: 20920755 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Targets

HDAC ^[1]
(Cell-free assay)

~1.8 nM

In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. ^[1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. ^[2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HeLa	NVjMU5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\YZ\|ExNzNyL{WwJI5O	M17PclczKGh?	MWjEUXNQ	M4j0Z4lv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp\|pUQqH2pJIxwe3NiY3XscJMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4NUe0PEc,OjNzNkW3OFg9N2F-
HeLa	NXX3T\|BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHv0SIUzOCCwTR?=	M4jFTVczKGh?	M1GwU2ROW09?	NXLvXFdZUUN3MDDv[kAzOG6P	NUfvNFVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOlU4PDhpPkKzNVY2PzR6PD;hQi=>
HeLa	NFTYXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3riOVQxKG6P	MUi0PEBp	MVrEUXNQ	NEPyWZhKSzVyIH;mJFQxdk1?	Ml31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNkW3OFgoRjJ\|MU[1O\|Q5RC:jPh?=
HeLa	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPaNVAxKG6P	NEO5VGgzPCCq	M2ewPWROW09?	MorqTWM2OCCxZjCxNFBvVQ>?	M1PtO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MU[1O\|Q5Lz5{M{G2OVc1QDxxYU6=
Caco-2	NV30PWttTnWwY4Tpc44hSXO\|YYm=	NHr6VowyKML3TdMg	MmXRNlQhcA>?		M4r5ToRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MnG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOUWwO\|AoRjJ\|MUm1NFcxRC:jPh?=
HTK	MoDvSpVv[3Srb36gRZN{[Xl?	Mn[zNVAxNThyMH7N	NWfVWHJyPzJiaB?=		M3K5WYJtd2OtczDUS2Yu\|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ6NECwNkc,OjN{OESwNFI9N2F-
HTK	M3v3[mZ2dmO2aX;uJGF{e2G7	NEPsUms1ODBibl2=	MXu3NkBp		MXjpcohq[mm2czDUS2Yu\|rMkgKPJcoR2[2WmIF35c4Zq[nKxYnzhd5QhTGmoZnXy[Y51cWG2aX;u	NUPKVmxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyPFQxODJpPkKzNlg1ODB{PD;hQi=>
HEK293	M{PZfGZ2dmO2aX;uJGF{e2G7	MYOxJOK2VcLi	MYexPEBpyqB?		NH22OGxqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW\|	MkXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OES4OFgoRjJ\|Mki0PFQ5RC:jPh?=
SH-SY5Y	NGjFTFVHfW6ldHnvckBCe3OjeR?=	MYCyOVAhdk1?	NFfRZ2oyPiCq		NFjWbYxkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW\|aYOsJJVxfGGtZTDhcoQh\W[obIX4	Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|Mk[0NlIoRjJ\|M{K2OFIzRC:jPh?=
THP1	NXfSV2o1SXCxcITvd4l{KEG\|c3H5	NGLidGgyKM7:TR?=	NVrEUWd[OjRiaB?=		MYfpcoR2[2W\|wrDj[YxtKGSnYYTo	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyMEWxPUc,OjN2MEC1NVk9N2F-
K562	M{H1SWFxd3C2b4Ppd{BCe3OjeR?=	M3zzeFEh\|ryP	MY[yOEBp		NFvafW5qdmS3Y3XzxsBk\WyuIHTlZZRp	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyMEWxPUc,OjN2MEC1NVk9N2F-
Kazumi	M4HMWGFxd3C2b4Ppd{BCe3OjeR?=	NYXZc\|RJOSEQvF2=	MkDHNlQhcA>?		MUjpcoR2[2W\|wrDj[YxtKGSnYYTo	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyMEWxPUc,OjN2MEC1NVk9N2F-
KG1	NFLjWGZCeG:ydH;zbZMhSXO\|YYm=	NVW3cIc1OSEQvF2=	MXuyOEBp		NXm0Z2NYcW6mdXPld:Kh[2WubDDk[YF1cA>?	MofPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEC1NVkoRjJ\|NECwOVE6RC:jPh?=
HL60	M3nNS2Fxd3C2b4Ppd{BCe3OjeR?=	NIHLOY0yKM7:TR?=	M13QOVI1KGh?		NFPD[5lqdmS3Y3XzxsBk\WyuIHTlZZRp	MoHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEC1NVkoRjJ\|NECwOVE6RC:jPh?=
HEL	MWDGeY5kfGmxbjDBd5NigQ>?	NX3OdXdCOC53IN88US=>	MnPONlQhcA>?	MVnleIhidm:u	MVPk[YNz\WG\|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=>	MnrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2M{C5OVcoRjJ\|NEOwPVU4RC:jPh?=
K562	M{LJZ2Z2dmO2aX;uJGF{e2G7	NWe5PGV2OC53IN88US=>	MUeyOEBp	Mni2[ZRp[W6xbB?=	NIDCTJRl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>?	MofGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2M{C5OVcoRjJ\|NEOwPVU4RC:jPh?=
LM8	M3\N[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nXUFAvOyEQvF2=	M4HUcVEzNTl4IHi=	NX3STW0xTE2VTx?=	NY\ITY5ScW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=>	NFy0OJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S1NVgyPyd-MkO0OVE5OTd:L3G+
MG-63	NWq0OllNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTjcmlTOC5\|IN88US=>	Mn7UNVIuQTZiaB?=	MYPEUXNQ	NYfv[49EcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=>	M3vySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEWxPFE4Lz5{M{S1NVgyPzxxYU6=
H1299	MYLGeY5kfGmxbjDBd5NigQ>?	MnPONE42KM7:TR?=	MUW0PEBp	MXTEUXNQ	Ml3VbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW\|c9MgJINwdWKrbnWge4l1cCC\|aXzpZolvcW5?	NEjVR5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S2NVk4PSd-MkO0OlE6PzV:L3G+
H1299	MVHGeY5kfGmxbjDBd5NigQ>?	MVSwMlUh\|ryP	MWe0PEBp	NH7K[5NFVVOR	MVPpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR4MUm3OUc,OjN2NkG5O\|U9N2F-
H1299	MlXzSpVv[3Srb36gRZN{[Xl?	NH63bmgxNjN\|4pETNeKhyrWP	MXuyOE81QCCq	Mn7VSG1UVw>?	M1T2eYlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm=	MmXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NkG5O\|UoRjJ\|NE[xPVc2RC:jPh?=
MCF7	MXXGeY5kfGmxbjDBd5NigQ>?	M2q1flAvODVvMjFOwG0>	NHG4[\|EzPCCq		MnrZdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM>	M2S3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEewOVQxLz5{M{S3NFU1ODxxYU6=
ARN8	MlrzSpVv[3Srb36gRZN{[Xl?	M{jaXVAvODVvMjFOwG0>	MXiyOEBp		MoG4doVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM>	M4fQOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEewOVQxLz5{M{S3NFU1ODxxYU6=
U373	MoCzSpVv[3Srb36gRZN{[Xl?	NWTBdXhlOC5{NT:wMlUwOSEQvF2=	NWDENmJDOjRiaB?=		MmX4bY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN?	NXj3V4J{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|QyPzFpPkKzOFc1OTdzPD;hQi=>
HASMCs	NYDkNFR5TnWwY4Tpc44hSXO\|YYm=	MV2wMVUxOCCwTR?=	Mm\HOkBl		M1y1foRwf25vcnXneYxifGW\|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6	MnPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUi0OlcoRjJ\|NUG4OFY4RC:jPh?=
MFE296	M2DwVWZ2dmO2aX;uJGF{e2G7	NIS3U3Q2ODBibl2=	NF7KO\|U2KGR?	MonGSG1UVw>?	M2m1eolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF	NVmzW4N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|A4PjlpPkKzOVMxPzZ7PD;hQi=>
EN1	MXHGeY5kfGmxbjDBd5NigQ>?	NFvUeVE2ODBibl2=	MWi1JIQ>	M1TtV2ROW09?	MUfpcoR2[2W\|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>?	NX75blZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N\|A4PjlpPkKzOVMxPzZ7PD;hQi=>
HEC1A	MnTHSpVv[3Srb36gRZN{[Xl?	NUjq[og4PTByIH7N	M37ocVUh\A>?	M{f3OmROW09?	NET3WWFqdmS3Y3XzJGwyS0GPwrDlfJBz\XO\|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?=	NIqzPIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzNFc3QSd-MkO1N\|A4Pjl:L3G+
ECC1	MVrGeY5kfGmxbjDBd5NigQ>?	NUT0U5UzPTByIH7N	M3qyTlUh\A>?	NVTxfoFXTE2VTx?=	M1n2XIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF	M2W1XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOwO\|Y6Lz5{M{WzNFc3QTxxYU6=
AGS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rzfFAvODF3LUGg{txO	NX\5cpVpPzJiaB?=		M4HTTIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5NEWwNlQoRjJ\|N{S1NFI1RC:jPh?=
Huh7	NVzsdY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3sc3Y{OSEQvF2=	NI\xXFIzPCCq	M4[xOmROW09?	M1rNSpJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh	NGDKWnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0N\|k{Oyd-MkO2OFM6OzN:L3G+
Lovo	NUfESodkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLhfo9xOC5{L{GuNE82NjBizszN	MlLINVIwOjRxM{[vOFghcA>?		MoH2bY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NULQWYVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3O\|AxODBpPkKzO\|cxODByPD;hQi=>
HCT1	M3j0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4q3NFAvOi9zLkCvOU4xKM7:TR?=	MkfTNVIwOjRxM{[vOFghcA>?		MlTjbY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NVPtfpJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3O\|AxODBpPkKzO\|cxODByPD;hQi=>
SUM190PT	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nlW\|UxNzFyMD:yOVAhdk1?	NHLLbXI1QCCq	NF:4TYJFVVOR	NFjM[YNqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl?	NEPw[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlY{QCd-MkO3PVI3Ozh:L3G+
SUM149PT	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS0Sm9TOi95LkWvNVAh\|ryP	NUXOTW9pPDhiaB?=	MnzOSG1UVw>?	NY\ES4lycW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm=	NHPxXno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlY{QCd-MkO3PVI3Ozh:L3G+
H1299	MW\BdI9xfG:\|aYOgRZN{[Xl?	NIHXeXcxNjVxMTFOwG0>	M1LHVlQ5KGh?	MWXleIhidm:u	MY\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NW\IWHl2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Olc6QTFpPkKzPFY4QTlzPD;hQi=>
A549	MVTBdI9xfG:\|aYOgRZN{[Xl?	NEGzT\|UxNjVxMTFOwG0>	MluwOFghcA>?	MmjC[ZRp[W6xbB?=	NVHXZpdScW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Nke5PVEoRjJ\|OE[3PVkyRC:jPh?=
H1299	M1nicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\DU5AxNjJ3L{CuOU8yKM7:TR?=	NU\nSZZoOjRxNEivO\|IhcA>?	NYmwcm1x\XSqYX7vcC=>	NH;lW5BqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NF36fIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i2O\|k6OSd-MkO4Olc6QTF:L3G+
A549	NH;GfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULCbWtxOC5{NT:wMlUwOSEQvF2=	NHezfWozPC92OD:3NkBp	M2fmOYV1cGGwb3y=	MkPpbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NYfnWnZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Olc6QTFpPkKzPFY4QTlzPD;hQi=>
H1299	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTzSldlOcLizszNxsA>	NULtW5l2OjRxNEivO\|IhcA>?	M3PhSIV1cGGwb3y=	MWPpcoNz\WG\|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzNk[wPUc,OjN7MU[2NFk9N2F-
PMNs	MYLGeY5kfGmxbjDBd5NigQ>?	M4\xVVMxKG6P	M1;mflQ5KGh?		NU\mdlhVcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6	NGrnfpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m4PFYyPyd-MkO5PFg3OTd:L3G+
CA46	M4\kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PUUVMwPi9zMj:yOE81QCCwTR?=	NFHtenc1QCCq		NHXS[JdqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi	M2rvXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[0PVUyLz5{NEC2OFk2OTxxYU6=
HCT116	M{ewXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYP5NYx5OC5{IN88US=>	NXXES3BKOTJiaB?=		Mmjw[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{MkKzNUc,OjRzMkKyN\|E9N2F-
HLEB3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\T[3BvOC52L{CuPEDPxE1?	MVO0PEBp	MkjoSG1UVw>?	M3rIfolv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NFSwUHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1O\|g4QCd-MkSxOVc5Pzh:L3G+
SRA01/04	NWfXRYQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYSwMlQwOC56IN88US=>	NXvWdm1JPDhiaB?=	M17VWGROW09?	MlXUbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3N{i3PEc,OjRzNUe4O\|g9N2F-
HLEB3	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSwMlIh\|ryP	MUm0PEBp	MWTEUXNQ	MXXzeZBxemW\|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3N{i3PEc,OjRzNUe4O\|g9N2F-
SRA01/04	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzvO24xNjJizszN	MUm0PEBp	MljMSG1UVw>?	MoKzd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM>	NWHtbo5pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVc5PzhpPkK0NVU4QDd6PD;hQi=>
A2780	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLXR\|MxNjB3LUKg{txO	MVyxNE8zPC92ODDo	MV;EUXNQ	MkHmcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NXjCUWIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNlM5ODFpPkK0NlI{QDBzPD;hQi=>
SKOV3	NHz2dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DrfVAvODVvMjFOwG0>	M1\vdFExNzJ2L{S4JIg>	MnzlSG1UVw>?	MVjt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NGfzdmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyN\|gxOSd-MkSyNlM5ODF:L3G+
Huh7	NXu5TlJETnWwY4Tpc44hSXO\|YYm=	Ml;4NE4yNzBwNT:xMlAh\|ryP	NEDqSWQzPGh?		M3zldpN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?=	NVu4RoJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3PzJpPkK0NlY6Pjd{PD;hQi=>
hMSCs	Ml\wSpVv[3Srb36gRZN{[Xl?	NHnkRog3NjJ3IH7N	M3zOUFI1KGh?	MmjZSG1UVw>?	MYrzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW\|	MmjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MUKzOVYoRjJ2M{GyN\|U3RC:jPh?=
HT29	NFLJXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\ENVgxKG6P	MkjBO\|IhcA>?		NF7NeG1KSzVyIH;mJFE5OCCwTR?=	MmCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NkiyOlUoRjJ2M{[4NlY2RC:jPh?=
RPE	NEC1NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjnNWk2OC5{L{CuOE8xNjhxMTFOwG0>	MVWyOE81QC95MjDo	NFrLfI5FVVOR	MmS3bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q>	NYe2VotLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVY3ODJpPkK0OFU3PjB{PD;hQi=>
U87 GBM	MX;GeY5kfGmxbjDBd5NigQ>?	M1HwclExOC93MECgUo0>	M4Hj[lQ5KGh?	NXq1WHRMOTByJTDleIhidm:u	NFvBSYpKdmS3Y3XzJHNmdmW\|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l?	MkDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NkS4OFEoRjJ2NE[0PFQyRC:jPh?=
U87 GBM	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zaSVExOC9\|MECvOVAxKG6P	NXTlWmxNPzJiaB?=	NYfDOJpkOTByJTDleIhidm:u	MY\y[YR2[2W\|IH3lZY4h[2WubDDueY1j\XJiYomgN\|EtKDV2LDDhcoQhPTkEoDW=	NXXqd5k4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OlQ5PDFpPkK0OFY1QDRzPD;hQi=>
ACP03	NFjUS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTnNlUxNzN3MD:1NFBvVQ>?	NVH4e245OjSq		M1nwOYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1?	NF;qdYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[2PFU1Pyd-MkS2Olg2PDd:L3G+
ACP02	NEjGXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXWyV5Z6OjVyL{O1NE82ODCwTR?=	MY[yOIg>		MYHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O	NH\Z[4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[2PFU1Pyd-MkS2Olg2PDd:L3G+
HeLa	MmT1SpVv[3Srb36gRZN{[Xl?	NEPXXJEydU1?	NEHlO3kxNjWq		NULtWHFu[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5	NVjCUmM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NFc1PzRpPkK0O\|A4PDd2PD;hQi=>
HMEC-1	M{f5SGZ2dmO2aX;uJGF{e2G7	M4TQ[VMxOG6P	NGPsSoczPGh?		MVfpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\sLiVlXHSnI{yqCvUl7B	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDdzME[zNUc,OjR5MUC2N\|E9N2F-
HeLa	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrNToIz\|ryP	NX;UflhFPDiq		NH;X[ndl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh2NkGzOUc,OjR6NE[xN\|U9N2F-
LNCaP	M2Szdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S2UFExOC1zMECwcm0>	MlHKNlRp		M3e4PGlEPTBib3[gN\|Axdk1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3NE[1PEc,OjR6NUS2OVg9N2F-
PC3	NXq0eG04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjqNVAxNTFyMEDuUS=>	NWTTUZN[OjSq		NH\2ZohKSzVyIH;mJFMxOG6P	NI\vXWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OFY2QCd-MkS4OVQ3PTh:L3G+
CNE2	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxNFAuPjBybl2=	M3rybVI1NzR6L{eybC=>		NWjkbW12cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz	NWHyUXJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5Olk6ODFpPkK0PVY6QTBzPD;hQi=>
HeLa	MnL3SpVv[3Srb36gRZN{[Xl?	NHjpTGUzPTCwTR?=	NV3MdYhIOT[q	MojzSG1UVw>?	MUHpcoNz\WG\|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi	NIrFTVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxOlY5QCd-MkWxNVY3QDh:L3G+
A549	NVPyUoZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[wMlAyNTBwOd88US=>	MknCO\|Jp	MX;EUXNQ	NIjWcHlKSzVyIH;mJFAvODcQvF2=	NXrWS2w5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOlk1QTFpPkK1NVY6PDlzPD;hQi=>
SKOV-3	NULGWG17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFWzc5kxNjBzLUCuPe69VQ>?	M3Lmb\|czcA>?	NXL2[XlPTE2VTx?=	NWHmXI1NUUN3MDDv[kAxNjN{zszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF4OUS5NUc,OjVzNkm0PVE9N2F-
A549	MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;UNE4yNTIQvF2=	M1TKU\|Q5cA>?	MljJSG1UVw>?	MXjJR\|UxKG:oIECuNljPxE1?	M2TWdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MU[5OFkyLz5{NUG2PVQ6OTxxYU6=
SKOV-3	M2LoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfONnoxNjFvMd88US=>	NE\tdok1QGh?	M1WxPGROW09?	MnWyTWM2OCCxZjCwMlfPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF4OUS5NUc,OjVzNkm0PVE9N2F-
A549	NXjIW4g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYGxMVEx\|ryP	NELyVFgzPGh?	M2HtRWROW09?	NGHFW4JKSzVyIH;mJFMvOs7:TR?=	NH\pT5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG2PVQ6OSd-MkWxOlk1QTF:L3G+
SKOV-3	M3X3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[xMVEx\|ryP	MUGyOIg>	NIrtZ2hFVVOR	NIm4TIhKSzVyIH;mJFUvPs7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF4OUS5NUc,OjVzNkm0PVE9N2F-
MCF7	NXfubnF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3SwUFAuPjBybl2=	MoTkNlRp	M{frbGROW09?	NYnq[ZJPUUN3MDDv[kA4PW6P	MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUK3NlEoRjJ3MUmyO\|IyRC:jPh?=
MDA-MB-231	NULme\|RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYSwMVYxOG6P	NVW2bJl4OjSq	MlW5SG1UVw>?	NHjrTJBKSzVyIH;mJFExOG6P	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF7MkeyNUc,OjVzOUK3NlE9N2F-
A431	MkS4SpVv[3Srb36gRZN{[Xl?	MWC1NI5O	MkPVNk83NzF{L{K0bC=>	Ml\XSG1UVw>?	NYnafWtP[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO\|aX;u	NEXXUIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3NVA3QSd-MkWzO\|ExPjl:L3G+
A431	NX\4UHpySXCxcITvd4l{KEG\|c3H5	MWKyM\|ExNzVyL{GwNI5O	Mmj2OFhp	MlXjSG1UVw>?	MnrGbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq	NIHORYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3NVA3QSd-MkWzO\|ExPjl:L3G+
PC3	NVv0dFJGTnWwY4Tpc44hSXO\|YYm=	NUCzfZNLOC5zzszN	MmqxOFhp	MlnySG1UVw>?	MXrpcoR2[2W\|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{S5PVcoRjJ3NEO0PVk4RC:jPh?=
SW480	MYXGeY5kfGmxbjDBd5NigQ>?	NF6zcFgxNjIQvF2=	NGPKdVM1QGh?	Ml;USG1UVw>?	M1TLcolv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ?	NEmweWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOFk6Pyd-MkW0N\|Q6QTd:L3G+
PC3	MXPGeY5kfGmxbjDBd5NigQ>?	MXSwMlHPxE1?	NWDhboY5PDiq	NXL5PVRxTE2VTx?=	NX7WfoN6[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u	M4LwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO0PVk4Lz5{NUSzOFk6PzxxYU6=
PC3	M4HJdGZ2dmO2aX;uJGF{e2G7	NG\ubmUxNjIQvF2=	NYTmdIx[PDiq	MXjEUXNQ	NHW2dWFz\X[ncoPld{BGVVR?	M{fXcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO0PVk4Lz5{NUSzOFk6PzxxYU6=
SW480	M1fZbmZ2dmO2aX;uJGF{e2G7	MkHuNE4y\|ryP	MkHQOFhp	MlnNSG1UVw>?	MoLyZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w	MmexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{S5PVcoRjJ3NEO0PVk4RC:jPh?=
SW480	NWn4OmhjTnWwY4Tpc44hSXO\|YYm=	NYiwc2xkOC5zzszN	MWO0PIg>	M3TSfWROW09?	NXHnN282emW4ZYLz[ZMhTU2W	M3nr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO0PVk4Lz5{NUSzOFk6PzxxYU6=
MEFs	NEL5SXJHfW6ldHnvckBCe3OjeR?=	NIjGcpY2\|ryP	M4LDXlE3cA>?		NFqwNIRqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25?	M2fCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEiyOlM1Lz5{NUS4NlY{PDxxYU6=
TE13	M{nJS2Fxd3C2b4Ppd{BCe3OjeR?=	MVOwMlPPxE1?	NG\QRpozPGh?		MkfBbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5OU[2OUc,OjV3N{m2OlU9N2F-
TE13	NWLJeXl4TnWwY4Tpc44hSXO\|YYm=	NUi1Z2I2OC5\|zszN	MkjmNlRp		M2LQOJVxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs	M13yflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe5OlY2Lz5{NUW3PVY3PTxxYU6=
HEK 293	NX;vWItGTnWwY4Tpc44hSXO\|YYm=	NVXxT2dJOC55zszN	NF7UPIszPGh?	NEnxXnNmfGijbn;s	MUTlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC\|dYLmZYNm	NHnMcIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4O\|A4QSd-MkW3PFcxPzl:L3G+
MDA-MB-231	M164bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCyOU01ODBibl2=	MVi0PEBp		NYjJUYZsUUN3MDDv[kAzPjNwMn7NxsA>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB3NUG5PEc,OjNyNUWxPVg9N2F-
MCF-7	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{e5SVI2NTRyMDDuUS=>	M1;YcFQ5KGh?		NWftZYZCUUN3MDDv[kAzOjBwNH7N	MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNUWxPVgoRjJ\|MEW1NVk5RC:jPh?=
ECC-1	NYrS[nl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnrfY8yODBibl2=	NVfIUYFvOjRiaB?=	NVm5T2Vu\XSqYX7vcC=>	MUXpcoNz\WG\|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB{OEiwN{c,OjNyMki4NFM9N2F-
HEC-1A	M{\KOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWxNFAhdk1?	M1TFd\|I1KGh?	MYjleIhidm:u	M3ezNYlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?=	NFnGR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CyPFgxOyd-MkOwNlg5ODN:L3G+
NHAC-kn	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL0bWYyOC9zMECvOVAxKG6P	M4nk[lEzKGh?	MUHEUXNQ	MYPJR\|UxKG:oIEWwNI5O	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzN{i3NUc,OjNyMUe4O\|E9N2F-
A549	NGTKdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnKNlUxKG6P	NYDMNGplPi15MjDo	NEnNcpVFVVOR	MYDjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl7NEe4NEc,OjJ7OUS3PFA9N2F-
MG-63	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrhWpE1OzByIH7N	Ml\KNVIhcA>?	MnW1SG1UVw>?	NVnZS5FocW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?=	NF30TXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke5PVM{QCd-MkK3PVk{Ozh:L3G+
MG-63	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXiU\|Q{ODBibl2=	NX3YfmE{OjRiaB?=	M4jyPGROW09?	NWfUWpB7cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?=	NFm5fFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke5PVM{QCd-MkK3PVk{Ozh:L3G+
MG-63	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnNN\|AxKG6P	MUi0PEBp	NVXMOJNITE2VTx?=	NEG1XnNqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn	Mm[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OUmzN\|goRjJ{N{m5N\|M5RC:jPh?=
HL60	NY\TWoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj2ZpIyPTBvM{WwJI5O	NE\aZpIzPCCq		NIjSZ\|JqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O	MoHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NUO3N\|koRjJ{N{WzO\|M6RC:jPh?=
U937	NF3CT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHUNVUxNTN3MDDuUS=>	MkPiNlQhcA>?		MYfpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N	NX3NPJd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OVM4OzlpPkKyO\|U{PzN7PD;hQi=>
SCC-6	NYfWeJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1uxV\|IxOC1\|MkCwJI5O	M1TaVlEzNzJ2L{S4JIg>	MW\EUXNQ	NV3oeGZ7cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MkfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUKzNlEoRjJ{NUWyN\|IyRC:jPh?=
U87	NX75VHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLmNVAxNTNyMDDu[y=>	NGO1SJAzPCCq		MWTpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO\|ImKCCjdDCyNFBv\w>?	NHLvbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3NFg1QSd-MkKyO\|A5PDl:L3G+
K562	M1frbWZ2dmO2aX;uJGF{e2G7	NXrVcZNUOSEQvF2=	NGfKd5YyOiCq	NIfsO4FFVVOR	NEHJWXRmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=>	M3;xU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUe5NVk5Lz5{MkG3PVE6QDxxYU6=
Reh	M{jp[mZ2dmO2aX;uJGF{e2G7	Mn62NE4{NzFizszN	NXfzVnI5OTJiaB?=	M1LqTmROW09?	NFT0bHlmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=>	MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzN{mxPVgoRjJ{MUe5NVk5RC:jPh?=
Mv1Lu	NVXQ[3h6TnWwY4Tpc44h[XO\|YYm=		NHm3T4gyQCCqcoO=		M3XEOGlv\HWldHnvckBw\iC5aXzkMZR6eGVicEKxJJBzd22xdHXyJIFkfGm4YYTpc44hcW5ibXnub{BOfjGOdTDj[YxteyCjZoTldkAyQCCqcoOgZpkhdHWlaX\ldoF{\SCjc4PhfUBz\WyjdHn2[UB1dyCkYYPhcEBt\X[nbDygSWMyODByIE2gNE4yQSEQvF2u	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzh6MUKzNkc,OTd6OEGyN\|I9N2F-
HeLa	M4fuWmZ2dmO2aX;uJIF{e2G7		MYCyOEBpenN?		MWDJcoR2[3Srb36gc4YheDJzIHX4dJJme3Orb36gbY4hcHWvYX6gTIVN[SClZXzsd{Bi\nSncjCyOEBpenNuIFXDNVAxOCB;IECuNFEyPSEQvF2u	M4PsbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{m3PFI3Lz5zOEO5O\|gzPjxxYU6=
Mv1Lu	M1;HZWZ2dmO2aX;uJIF{e2G7		MWWyOEBpenN?		NWf6Zo5KUW6lcnXhd4UhcW5iaIXtZY4hf2muZDD0fZBmKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hdWmwazDNelFNfSClZXzsd{Bi\nSncjCyOEBpenNiYomgdFIyKHC{b33veIVzKGG\|c3H5MEBGSzFyMECgQUAxNjB{IN88UU4>	MmXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe1O\|goRjJ2OUm3OVc5RC:jPh?=
HCT 116	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				Mom2TY4hfmm2cn:gZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiClb3zvckBk[W6lZYKgTGNVKDFzNjDj[YxteyCmZYTldo1qdmWmIHL5JG1OXCCjc4PhfUwhTUN3MDC9JFEh\|ryPLh?=	M{fYb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNUm3OFE{Lz5zMUW5O\|QyOzxxYU6=
T24	NWLIbIZ5TnWwY4Tpc44h[XO\|YYm=				MXTDc45k\W62cnH0bY9vKG:oIHPvcZBwfW6mIILldZVqemWmIH\vdkBi[2W2eXzheIlwdiCxZjDobZN1d26nLUSgbY4hcHWvYX6gWFI1KGOjbnPldkBk\WyuczygSWM2OCB;IEGg{txONg>?	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3OUe0NVMoRjFzNUm3OFE{RC:jPh?=
T24	NW\mPIV[TnWwY4Tpc44h[XO\|YYm=				MoW1TY5pcWKrdHnvckBw\iCjY3X0fYxifGmxbjDv[kBpcXO2b37lMVQhcW5iaIXtZY4hXC1{NDDjZY5k\XJiY3XscJMtKEWFNUCgQUAyKM7:TT6=	MlfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR4MUOzNVIoRjF2NkGzN\|EzRC:jPh?=
T24	M1XvUmZ2dmO2aX;uJIF{e2G7				Mn;CTY5pcWKrdHnvckBw\iCjY3X0fYxifGmxbjDv[kBpcXO2b37lMVQhcW5iaIXtZY4hXC1{NDDjZY5k\XJiY3XscJMtKEWFNUCgQUA1KM7:TT6=	NYX5OIZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS2NVM{OTJpPkG0OlE{OzF{PD;hQi=>
T24	MnLESpVv[3Srb36gZZN{[Xl?				NVriUFNTUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25iaX6gbJVu[W5iVEK0JINmdGy\|LDDFR\|UxKD1iMD6wNUDPxE1w	NUDmOVZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVE1PjZpPkG5NVEyPDZ4PD;hQi=>
T24	NH:3Z2JHfW6ldHnvckBie3OjeR?=				NY\VSGhPUW6mdXP0bY9vKG:oIHjpd5RwdmViSEOgZYNmfHmuYYTpc44hcW5iaIXtZY4hXDJ2IHPlcIx{NCCHQ{WwJF0hOC5yMTFOwG0v	NY\WUGFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVE1PjZpPkG5NVEyPDZ4PD;hQi=>
HepG2	M4rkbmZ2dmO2aX;uJIF{e2G7				NV7t[XV6XXBvcnXneYxifGmxbjDv[kB1emGwc3PybZB1cW:wYXygZYN1cX[rdImgc4YhcHWvYX6gR2xCNTFicILvcY91\XJicnXnbY9vKC1zMEW1JJRwKC14MnLwJJRz[W6\|ZnXjeIVlKGmwIFjldGczKGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuN\|gh\|ryPLh?=	NYG2fYRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVYyODJpPkK1OVU3OTB{PD;hQi=>
HeLa	MYHGeY5kfGmxbjDhd5NigQ>?				NGP2[m5KdmirYnn0bY9vKG:oIFjERWM3KGmwIHj1cYFvKEinTHGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXL1cIlvKGSnYXPleJlt[XSrb36gbY5kfWKjdHXkJIZweiCxdnXycolocHRiYomgZ2VNUVODLDDFR\|UxKD1iMD6wNFUzKM7:TT6=	M{DIcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkGxPVE6Lz5{Nk[xNVkyQTxxYU6=
HL60	MlSxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH;kcXEzPCCqcoO=		MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDBwNUmg{txONg>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3NEmxPEc,Ojl2NUS5NVg9N2F-
MDA-MB-435	NIjHXIVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3:2ZlI1KGi{cx?=		NVrXXI15SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzLke4JO69VS5?	NFTDXJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1OFkyQCd-Mkm0OVQ6OTh:L3G+
K562	M2r6O2Z2dmO2aX;uJIF{e2G7				MVLJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgdIFzfGmjbHz5JJB2emmoaXXkJIhqe3SxbnWg[IVi[2W2eXzhd4Uhd2ZiaIXtZY4hdGW3a3XtbYEhUzV4MjDj[Yxtey5uIFnDOVAhRSByLkCwOFYh\|ryPLh?=	M3nTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEK1NVExLz5zMESyOVEyODxxYU6=
A20	MX7GeY5kfGmxbjDhd5NigQ>?				MkLDTY4hfmm2cn:g[o9zKGGwdHmtTGRCSzFiKFjpd5RwdmViZHXhZ4V1gWyjc3WgNUkh[WO2aY\peJkhcW5ibX;1d4UhSTJyIHPlcIx{NCCLQ{WwJF0hOC5yMEKg{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTl4MES4PUc,OTF7NkC0PFk9N2F-
K 562	NFrO[mlHfW6ldHnvckBie3OjeR?=				MkTpTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhqe3SxbnWg[IVi[2W2eXzhd4UhMEiGQVOpJIlvKEtiNU[yJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyxiSVO1NEA:KDBwMECzOEDPxE1w	M2TJUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmyOFc{Lz5zNEW5NlQ4OzxxYU6=
friend cell	MlnISpVv[3Srb36gZZN{[Xl?				NU[0d2NGUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4Sg[pJq\W6mIHPlcIx{KHC{b3zp[oVz[XSrb36sJGlEPTBiPTCwMlA1KM7:TT6=	NVHBfYNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUS2NVM{OTJpPkG0OlE{OzF{PD;hQi=>
SNU-16	MULGeY5kfGmxbjDhd5NigQ>?				M4L0bmlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJcXO2b37lJIRm[WOndInsZZNmKCiKRFHDLUBnem:vIGPOWU0yPiBqaIXtZY4h\2G\|dILpZ{Bi\GWwb3PhdoNqdm:vYTmgZ4VtdHNuIFnDOVAhRSByLkC1N\|I6KM7:TT6=	MoHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR4NkeyNlcoRjF2Nk[3NlI4RC:jPh?=
melanoma B16/BL6	M{XTS2Z2dmO2aX;uJIF{e2G7				M2HZe2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpcXO2b37lJIRm[WOndInsZZNmeyBqSFTBR\|EqKHC{ZYDhdoVlKG[{b32gcY92e2VibXXsZY5wdWFiQkG2M2JNPiClZXzsd{whUUN3MDC9JFAvODF7IN88UU4>	M1[0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlI3Lz5zNUGwPVYzPjxxYU6=
melanoma B16/BL6	MlfGSpVv[3Srb36gZZN{[Xl?				M3PjPWlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpcXO2b37lJIRm[WOndInsZZNmKCiKRFHDOEkheHKncHHy[YQh\nKxbTDtc5V{\SCvZXzhco9u[SCEMU[vRmw3KGOnbHzzMEBKSzVyIE2gNE4xOiEQvF2u	NU\nNnRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxNFk3OjZpPkG1NVA6PjJ4PD;hQi=>
melanoma B16/BL6	M3vNPGZ2dmO2aX;uJIF{e2G7				NXfK[INmUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGirc4TvcoUh\GWjY3X0fYxie2ViNjDwdoVx[XKnZDDmdo9uKG2xdYPlJI1mdGGwb33hJGIyPi:ETE[gZ4VtdHNuIFnDOVAhRSByLkCyPEDPxE1w	M4PNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlI3Lz5zNUGwPVYzPjxxYU6=
melanoma B16/BL6	MoDsSpVv[3Srb36gZZN{[Xl?				NWH4[YxxUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGirc4TvcoUh\GWjY3X0fYxie2ViODDwdoVx[XKnZDDmdo9uKG2xdYPlJI1mdGGwb33hJGIyPi:ETE[gZ4VtdHNuIFnDOVAhRSByLkC0JO69VS5?	M3f6[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlI3Lz5zNUGwPVYzPjxxYU6=
293T	NGjJfYJHfW6ldHnvckBie3OjeR?=				M3LZbmlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SB2IIDy[ZBiemWmIH\yc40hOjl\|VDDj[YxteyxiSVO1NEA:KDBwMEKg{txONg>?	MnPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyNlQoRjF3NEW0NlI1RC:jPh?=
293T	M3LIWGZ2dmO2aX;uJIF{e2G7				M2LJWGlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBzIIDy[ZBiemWmIH\yc40hOjl\|VDDj[YxteyxiSVO1NEA:KDBwMEKg{txONg>?	NXL5N2NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0OVQzOjRpPkG1OFU1OjJ2PD;hQi=>
293T	NGnOfFJHfW6ldHnvckBie3OjeR?=				MWLJcohq[mm2aX;uJI9nKGi3bXHuJIhqe3SxbnWg[IVi[2W2eXzhd4UhPiCycnXwZZJm\CCocn;tJFI6O1RiY3XscJMtKEmFNUCgQUAxNjB{IN88UU4>	MkPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyNlQoRjF3NEW0NlI1RC:jPh?=
293T	NYDMdog3TnWwY4Tpc44h[XO\|YYm=				M2rPOmlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SB6IIDy[ZBiemWmIH\yc40hOjl\|VDDj[YxteyxiSVO1NEA:KDBwMESg{txONg>?	MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyNlQoRjF3NEW0NlI1RC:jPh?=
HeLa	MV\GeY5kfGmxbjDhd5NigQ>?				MnnDTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{kh\nKxbTDI[WxiKGOnbHzzJJdqfGhic4Xid5Rz[XSnIEXhMEBKSzVyIE2gNE4xPTR3IN88UU4>	NFTpUG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OlI3Pyd-MUW0OVYzPjd:L3G+
HCT116	M1nldGFvfGmycn;sbYZmemG2aY\lJIF{e2G7				MlG1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDIR3QyOTZiY3XscJMtKEmFNUCgQUAxNjByMUOg{txONg>?	M2SxR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUC0PFkxLz5zNkmwOFg6ODxxYU6=
H1299	NYLn[2NoSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NEXSfo9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGgyOjl7IHPlcIx{NCCLQ{WwJF0hOC5zIN88UU4>	NWnrUGx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NFQ5QTBpPkG2PVA1QDlyPD;hQi=>
H661	MlrFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NV\ZWndZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBJPjZzIHPlcIx{NCCLQ{WwJF0hOC5\|IN88UU4>	NH:5SWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmwOFg6OCd-MU[5NFQ5QTB:L3G+
H661	MoLZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M176flQ5KGi{cx?=		NFTXUJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGg3PjFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFAvODh3IN88UU4>	MknqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MkS3O\|MoRjF5NkK0O\|c{RC:jPh?=
WiDr	M1zrdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				Ml[0TY5pcWKrdHnvckBw\iCVQWCxN\|AhdWWmaXH0[YQh[2WubDDndo94fGhiaX6gbJVu[W5iV3nEdkBk\WyuczygTWM2OCB;IECuOVc4PiEQvF2u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ2M{GxNkc,OTd4NEOxNVI9N2F-
U251	MmTiSpVv[3Srb36gZZN{[Xl?				M1u5d2lvcGmkaYTpc44hd2ZiU1HQNVMxKGmwIG\FS2Yue3SrbYXsZZRm\CCqdX3hckBWOjVzIHPlcIx{KGK7IGDMRXAhemWyb4L0[ZIh\2WwZTDhd5NigSxiSVO1NEA:KDBwNkGxNkDPxE1w	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ2M{GxNkc,OTd4NEOxNVI9N2F-
293T	MYLGeY5kfGmxbjDhd5NigQ>?				NEfCSIJKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOxJIV5eHKnc4Pl[EBqdiB{OUPUJINmdGy\|LDDJR\|UxKD1iMD6wNFE6KM7:TT6=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzh6MUKzNkc,OTd6OEGyN\|I9N2F-
293T	MmTFSpVv[3Srb36gZZN{[Xl?				NUf0WWlRUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOEBmgHC{ZYPz[YQhcW5iMkmzWEBk\WyuczygTWM2OCB;IECuNFAzKM7:TT6=	NVeweIJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4PFEzOzJpPkG3PFgyOjN{PD;hQi=>
293T	M3m5UGZ2dmO2aX;uJIF{e2G7				MmXYTY5pcWKrdHnvckBw\iCvb4Xz[UBJTEGFNjDlfJBz\XO\|ZXSgbY4hOjl\|VDDj[YxteyxiSVO1NEA:KDBwMECyPEDPxE1w	Mnz6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd6OEGyN\|IoRjF5OEixNlMzRC:jPh?=
H661	MoPZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3exRlQ5KGi{cx?=		NH;XdpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGg3PjFiY3XscJMh[W[2ZYKgOFghcHK\|LDDJR\|UxKD1iMD6wPFUh\|ryPLh?=	NYTXVXRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe4PVc5OjRpPkG3PFk4QDJ2PD;hQi=>
293T	MmHKSpVv[3Srb36gZZN{[Xl?				M1L1VWlvcGmkaYTpc44hd2ZiSFTBR\|Eh\XiycnXzd4VlKGmwIEK5N3Qh[2WubIOsJGlEPTBiPTCwMlE6KM7:TT6=	M2ewclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUCwPVEyLz5zN{mwNFkyOTxxYU6=
293T	MVvGeY5kfGmxbjDhd5NigQ>?				MnjmTY5pcWKrdHnvckBw\iCKRFHDOEBmgHC{ZYPz[YQhcW5iMkmzWEBk\WyuczygTWM2OCB;IECuNkDPxE1w	NYS3VndPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5NFA6OTFpPkG3PVAxQTFzPD;hQi=>
293T	NVK3[3pbTnWwY4Tpc44h[XO\|YYm=				MlPiTY5pcWKrdHnvckBw\iCKRFHDOkBmgHC{ZYPz[YQhcW5iMkmzWEBk\WyuczygTWM2OCB;IECuNlgh\|ryPLh?=	M4LrSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUCwPVEyLz5zN{mwNFkyOTxxYU6=
NIH3T3	NHLMNXpHfW6ldHnvckBie3OjeR?=				NXTNRo1VUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSCneIDy[ZN{\WRiaX6gUmlJO1R\|IHPlcIx{NCCLQ{WwJF0hOC5yMkGg{txONg>?	NGDhUXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{myPVc6QCd-MUe5Nlk4QTh:L3G+
human 293	MWrGeY5kfGmxbjDhd5NigQ>?				MmDzTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOEBmgHC{ZYPz[YQhcW5iMkmzJINmdGy\|LDDJR\|UxKD1iMD6wN\|Qh\|ryPLh?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl{OUe5PEc,OTd7Mkm3PVg9N2F-
mouse 293	M3PYWGZ2dmO2aX;uJIF{e2G7				MYLJcohq[mm2aX;uJI9nKG2xdYPlJJJm[2:vYnnuZY51KEiGQVO2JIV5eHKnc4Pl[EBqdiB{OUOgZ4VtdHNuIFnDOVAhRSByLkC4NUDPxE1w	NEOyT289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{myPVc6QCd-MUe5Nlk4QTh:L3G+
SKBR3	NXT3TGhsSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONQmKzJINmdGy\|LDDJR\|UxKD1iMD6wNkDPxE1w	NY[2cGNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
MM96L	MoW4SpVv[3Srb36gZZN{[Xl?				NFzZXmNKdmirYnn0bY9vKG:oIHj1cYFvKE2POU\MJINmdGy\|LDDJR\|UxKD1iMD6wN{DPxE1w	MlLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
SNU16	MXjGeY5kfGmxbjDhd5NigQ>?				MX3Jcohq[mm2aX;uJI9nKEiGQVOg[pJwdSCqdX3hckBUVlVzNjDj[YxteyxiSVO1NEA:KDBwMEWzJO69VS5?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
A549	Mk\VRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5?	NV\4cVZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
MKN45	NUiyZ2o4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NGS0fI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzMEBKSzVyIE2gNE4yKM7:TT6=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
SQ20B	MV\GeY5kfGmxbjDhd5NigQ>?				NGL1WHBKdmirYnn0bY9vKG:oIHj1cYFvKFOTMkDCJINmdGy\|LDDJR\|UxKD1iMD6yJO69VS5?	NHfyTJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
neonatal foreskin fibroblasts	MoPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MoG4S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gcoVwdmG2YXyg[o9z\XOtaX6g[oljem:kbHHzeJMh[2WubIOsJGlEPTBiPTCwMlIh\|ryPLh?=	NGDUO\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U2PCd-MUiyOFc2PTR:L3G+
HeLa	MkTDSpVv[3Srb36gZZN{[Xl?				MYLJcohq[mm2aX;uJI9nKEiGQVOg[pJwdSCqdX3hckBJ\UyjIHPlcIx{NCCLQ{WwJF0hOC5\|IN88UU4>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
MM96L/NFF	NFPQTGFHfW6ldHnvckBie3OjeR?=				MlzBV4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJIh2dWGwIF3NPVZNKGOnbHzzJJRwKEmFNUCg[o9zKGi3bXHuJG5HTiClZXzsd{whUUN3MDC9JFYvPyEQvF2u	M4rDW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
293T	MVzGeY5kfGmxbjDhd5NigQ>?				NIK3fYFKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOxJIV5eHKnc4Pl[EBqdiB{OUPUJINmdGy\|LDDJR\|UxKD1iMD6wN\|Y3KM7:TT6=	NHXyVIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO5O\|gzPid-MUizPVc5OjZ:L3G+
293T	NHHnSI5HfW6ldHnvckBie3OjeR?=				MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2IHX4dJJme3OnZDDpckAzQTOWIHPlcIx{NCCLQ{WwJF0hOC5yNkK5JO69VS5?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN7N{iyOkc,OTh\|OUe4NlY9N2F-
293T	M4HHSGZ2dmO2aX;uJIF{e2G7				M33RfWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{[g[ZhxemW\|c3XkJIlvKDJ7M2SgZ4VtdHNuIFnDOVAhRSByLkC4N\|Mh\|ryPLh?=	Mn63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OUe4NlYoRjF6M{m3PFI3RC:jPh?=
HeLa	MV;GeY5kfGmxbjDhd5NigQ>?				NVvpZopvUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDJIlvKEinTHGgZ4VtdHNiYomg[oxwfXJiZHWgcJl{KGG\|c3H5MEBKSzVyIE2gNE4xODVizszNMi=>	NWPVZnBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPVc5OjdpPkG4N\|k4QDJ5PD;hQi=>
S2	MoDNSpVv[3Srb36gZZN{[Xl?				NVPQd2VWUW6qaXLpeIlwdiCxZjDQcIF{dW:maYXtJIZidGOrcHHyeY0hUESDQ{Gg[ZhxemW\|c3XkJIlvKES{b4PvdIhqdGFibXXsZY5w\2G\|dHXyJHMzKGOnbHzzMEBKSzVyIE2gNE4xODB4IN88UU4>	Mn7IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MUe0OVAoRjF7M{G3OFUxRC:jPh?=
NCI-H661	MknERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEXvSHY1QCCqcoO=		MoewRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFY3OSClZXzsd{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBKSzVyIE2gNE4yKM7:TT6=	NVnPOohORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzPFU3ODBpPkG5N\|g2PjByPD;hQi=>
NIH3T3	M3S2NmZ2dmO2aX;uJIF{e2G7				NEjjb4hKdmirYnn0bY9vKG:oIFjERWMyKGmwIHj1cYFvKE6LSEPUN{Bk\WyuczDifUBz[WSrb33leJJq[yCqaYP0c45mKGSnYXPleJlt[XSrb36gZZN{[XluIFnDOVAhRSByLkCwOkDPxE1w	MlnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2NUe2OVkoRjF7NEW3OlU6RC:jPh?=
HeLa	M3fucmZ2dmO2aX;uJIF{e2G7				NV61fVh7UW6qaXLpeIlwdiCxZjDISGFEKG[{b32gbJVu[W5iSHXMZUBk\WyuczDifUBndHWxcn;n[Y5q[yCnbor5cYUh[XO\|YYmsJGlEPTBiPTCwMlMh\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR3N{[1PUc,OTl2NUe2OVk9N2F-
ML1	NHv4[4hCdnSrdIXtc5Ih[XO\|YYm=				MnHSRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViTVyxJINmdGy\|LDDJR\|UxKD1iMD6yOUDPxE1w	M1\JOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO0OVM1Lz5zOUWzOFU{PDxxYU6=
HCT116	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		NEmy[XY{KGSjeYO=		Ml7OR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFMh\GG7czDifUBYW1RvMTDhd5NigSxiSVO1NEA:KDBwODFOwG0v	M1HaNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEWyNlI3Lz5{MES1NlIzPjxxYU6=
HCT116	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWn4TIRvPDhiaILz		M4C2NGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yNEOg{txONg>?	MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyN{OxOlAoRjJzMEezNVYxRC:jPh?=
H460	MkjoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlHrOFghcHK\|		MWPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5M{G2NEc,OjFyN{OxOlA9N2F-
DMS53	M4\IWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NH;5VJEzKGSjeYO=		NFL2T5JEgXSxc4TheIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gSG1UPTNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgNkBl[Xm\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODJ3IN88UU4>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTVyNEKxOEc,OjF3MESyNVQ9N2F-
HeLa	MoXoSpVv[3Srb36gZZN{[Xl?		NXz5PGRnOjBibXnudy=>		NIW4PIlKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUGWOYTDj[YxteyC3c3nu[{BC[y2DcnetS4x6NUy7czjBZ{kuSU2FIHHzJIZtfW:{ZYPj[Y51KHO3YoP0doF1\SCjZoTldkAzOCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMECzJO69VS5?	NX\PUo9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2NlE5QDNpPkKxOlIyQDh\|PD;hQi=>
Sf9	MWDGeY5kfGmxbjDhd5NigQ>?		M4SyVFEhcHJ?		NEDaNYVKdmirYnn0bY9vKG:oIF6geIVzdWmwYXygbIV5[Wirc4Tp[Ilv\S22YXfn[YQhcHWvYX6gTGRCSzhiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuPVYh\|ryPLh?=	NVXYfZZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NlM4OzNpPkKxO\|I{PzN\|PD;hQi=>
MCF7	MlHGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIrNN3E1QCCqcoO=		MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNzFOwG0v	NG[5Npg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS2OVA6OSd-MkK0OlUxQTF:L3G+
BE(2)-C	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHj2cok4OiCqcoO=		MmTQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCERTiyLU1EKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNFUh\|ryPLh?=	M3PsXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUOyN\|E3Lz5{MkmzNlMyPjxxYU6=
Sf9	NGD0WW9HfW6ldHnvckBie3OjeR?=		NXzWTo83OiCqcoO=		MUjJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiaX7jeYJifGWmIH\vdkAzKGi{czD1d4lv\yCUSFvLMWFkKG[udX;yc4dmdmmlIIP1ZpN1emG2ZTygTWM2OCB;IECuNFAyOiEQvF2u	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzByOUKwN{c,OjNyMEmyNFM9N2F-
Sf9	NYW3T4NITnWwY4Tpc44h[XO\|YYm=		M1TzeVIhcHK\|		M2DNXmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Eh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDpcoN2[mG2ZXSg[o9zKDJiaILzJJV{cW6pIGLIT2suSWNiZnz1c5Jw\2WwaXOgd5Vje3S{YYTlMEBKSzVyIE2gNE4xODVizszNMi=>	NUDtPFZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNFkzODNpPkKzNFA6OjB\|PD;hQi=>
A2780	M2TiWmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MknrO\|IhcHK\|		NH3YbGREgXSxdH;4bYNqfHliYXfhbY5{fCClaYPwcIF1cW5icnXzbZN1[W62IHj1cYFvKEF{N{iwJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkKyJO69VS5?	M4n5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
A2780	MXLGeY5kfGmxbjDhd5NigQ>?		MYGxPEBpenN?		MoTETY5pcWKrdHnvckBw\iCKRFHDJIlvKGOrc4DsZZRqdiC{ZYPpd5RidnRiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhOThiaILzJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwMkWg{txONg>?	NEO4TIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
A2780	NEHEW2JEgXSxdH;4bYNqfHliYYPzZZk>		M2DyXVczKGi{cx?=		MlPNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjlizszNMi=>	NYfIb3Q1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVI3ODNpPkKzNlUzPjB\|PD;hQi=>
A2780	MULGeY5kfGmxbjDhd5NigQ>?		NE\RcYMyQCCqcoO=		MU\Jcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgNVghcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvPDNizszNMi=>	M2PvZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
Sf9	NHu0fWtHfW6ldHnvckBie3OjeR?=				MnvlTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOvd4Y6KGOnbHzzJJV{cW6pIGLIT2tC[yCjczDzeYJ{fHKjdHWsJGlEPTBiPTCwMlAxODlizszNMi=>	M1TEe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUC1OlgxLz5{M{mwOVY5ODxxYU6=
Sf9	MUfGeY5kfGmxbjDhd5NigQ>?				MUDJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz;z[lkh[2WubIOgeZNqdmdiUljLT2FkKGG\|IIP1ZpN1emG2ZTygTWM2OCB;IECuNFA2KM7:TT6=	NV3DWlRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
Sf9	NF;TPFNHfW6ldHnvckBie3OjeR?=				NFjCS3RKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWMzKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{9{\jliY3XscJMhfXOrbnegVmhMU0GlIHHzJJN2[nO2cnH0[UwhUUN3MDC9JFAvODB3IN88UU4>	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEW2PFAoRjJ\|OUC1OlgxRC:jPh?=
Sf9	MV;GeY5kfGmxbjDhd5NigQ>?				M1:xSmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|ExKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{9{\jliY3XscJMhfXOrbnegVmhMU0GlIHHzJJN2[nO2cnH0[UwhUUN3MDC9JFAvODB7IN88UU4>	MnH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEW2PFAoRjJ\|OUC1OlgxRC:jPh?=
Sf9	NWnnZWNPTnWwY4Tpc44h[XO\|YYm=				MYTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOvd4Y6KGOnbHzzJJV{cW6pIGLIT2tC[yCjczDzeYJ{fHKjdHWsJGlEPTBiPTCwMlAyPzNizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyNU[4NEc,OjN7MEW2PFA9N2F-
Sf9	M3fIS2Z2dmO2aX;uJIF{e2G7				MX7Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO4JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz;z[lkh[2WubIOgeZNqdmdiUljLRYNMSWNiYYOgd5Vje3S{YYTlMEBKSzVyIE2gNE4yOjlizszNMi=>	NX3iTotvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
MOLT4	M3W0TWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIrWeok4OiCqcoO=		M37zVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1QVFR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IECuNFMh\|ryPLh?=	Mn;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NkC2NlcoRjJ2OU[wOlI4RC:jPh?=
A549	NF3ac4hEgXSxdH;4bYNqfHliYYPzZZk>		NGD1[5I4OiCqcoO=		NGW1RVJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IECuNFUh\|ryPLh?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4ME[yO{c,OjR7NkC2Nlc9N2F-
MCF7	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		NVjRSnA{PzJiaILz		M{HodWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6wOkDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4ME[yO{c,OjR7NkC2Nlc9N2F-
HL60	NWjXe3gzS3m2b4TvfIlkcXS7IHHzd4F6		NXXO[XMxPzJiaILz		M2O4fmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6wPEDPxE1w	NIO4dos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NFYzPyd-MkS5OlA3Ojd:L3G+
BGC823	NELoSnFEgXSxdH;4bYNqfHliYYPzZZk>		Mn;EO\|IhcHK\|		NV3sVFJiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODhizszNMi=>	NVj2NoQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlA3OjdpPkK0PVYxPjJ5PD;hQi=>
HuH7	M{L0RWN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mnm2O\|IhcHK\|		MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	M3XLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[wOlI4Lz5{NEm2NFYzPzxxYU6=
U937	MnPQR5l1d3SxeHnjbZR6KGG\|c3H5		MXq3NkBpenN?		NYLDfnN3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTl\|NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	NUHNfWZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlA3OjdpPkK0PVYxPjJ5PD;hQi=>
HeLa	Mk\pR5l1d3SxeHnjbZR6KGG\|c3H5		MVW3NkBpenN?		MkCxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSByLkGxJO69VS5?	NH7BXGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NFYzPyd-MkS5OlA3Ojd:L3G+
NCI-H1975	NXrhd3VPS3m2b4TvfIlkcXS7IHHzd4F6		M3eyXFczKGi{cx?=		NUnNdZlYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDBwMkGg{txONg>?	M{fab\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[wOlI4Lz5{NEm2NFYzPzxxYU6=
K562	NY\UbnBDS3m2b4TvfIlkcXS7IHHzd4F6		Mm\KO\|IhcHK\|		NX\qT3JuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlQyKM7:TT6=	M176NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[wOlI4Lz5{NEm2NFYzPzxxYU6=
HEK293	MljQR5l1d3SxeHnjbZR6KGG\|c3H5		M{C2UVk3KGi{cx?=		M1jPe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhGUzJ7MzDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zNjFOwG0v	Mm\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NU[xNFIoRjJ3NUW2NVAzRC:jPh?=
LO2	NXfafmFDS3m2b4TvfIlkcXS7IHHzd4F6		NEfre3A6PiCqcoO=		MoftR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG8zKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlIyKM7:TT6=	NGLzeoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OlExOid-MkW1OVYyODJ:L3G+
HeLa	NV7lN4JYS3m2b4TvfIlkcXS7IHHzd4F6		MlzOPVYhcHK\|		NFe3dGlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjh3IN88UU4>	MlzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NU[xNFIoRjJ3NUW2NVAzRC:jPh?=
HepG2	MnHCR5l1d3SxeHnjbZR6KGG\|c3H5		MYi5OkBpenN?		MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE46PiEQvF2u	MlfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NU[xNFIoRjJ3NUW2NVAzRC:jPh?=
U2OS	MnTMR5l1d3SxeHnjbZR6KGG\|c3H5		NHvTN4U6PiCqcoO=		MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVNm9UKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOE46OyEQvF2u	MorjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NU[xNFIoRjJ3NUW2NVAzRC:jPh?=
Sf9	M{H0dGZ2dmO2aX;uJIF{e2G7		NVnU[VdGQTBibXnudy=>		MUnJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKHKnY3;tZolv[W62IF6teIVzdWmwYXygS3NVNXSjZ3fl[EBJTEGFNjCoNUB1dyBzMkG1JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy\|IIXzbY5oKFKKSz3LLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgPVAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjByMUexOkDPxE1w	NGHococ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3PCd-MkewOlA4PjR:L3G+
Sf21	MYXGeY5kfGmxbjDhd5NigQ>?		NVLXTmxWPjBibXnudy=>		NXPaZ2VoUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBENXSncn3pcoFtKE[OQVetTIl{NXSjZ3fl[EBJTEGFMTCoNUB1dyB2OEKgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy\|IIXzbY5oKFKKSz3LLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgOlAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjByNkW3OEDPxE1w	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2OEc,OjdyNkC3OlQ9N2F-
insect cell	MYnGeY5kfGmxbjDhd5NigQ>?		NEPEXHc3OCCvaX7z		NVW1fY1lUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBENXSncn3pcoFtKEeVVD30ZYdo\WRiSFTBR\|IhMDFidH:gOFg5KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW\|aX7nJHJJUy2NKFHjLU1CVUNiYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiNkCgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlAyODVzIN88UU4>	NIXOc\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3PCd-MkewOlA4PjR:L3G+
insect cell	NVL6dWFNTnWwY4Tpc44h[XO\|YYm=		NXi4U\|JsPjBibXnudy=>		NVS3UItqUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDy[YNwdWKrbnHueEBENXSncn3pcoFtKEircz30ZYdo\WRiSFTBR\|MhMDFidH:gOFI5KHKnc3nkeYV{MS:qdX3hckBz\WOxbXLpcoFvfCCQLYTldo1qdmGuIFfTWE11[WepZXSgUmNQWjJiZYjwdoV{e2WmIHnuJIlve2WldDDj[YxteyC3c3nu[{BTUEtvSzjBZ{kuSU2FIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IE[wJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xOTFyNzFOwG0v	M{PYbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|Y1Lz5{N{C2NFc3PDxxYU6=
insect cell	MXPGeY5kfGmxbjDhd5NigQ>?				MXTJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KE5vdHXycYlv[WxiSHnzMZRi\2enZDDISGFEOTFiKEGgeI8hOzR5IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hcW6\|ZXP0JINmdGy\|L3LhZ5Vtd3[rcoXzJIV5eHKnc4Ppc44he3m\|dHXtJJV{cW6pIGLIT{1MMEGlKT3BUWMh[XNic4Xid5Rz[XSnIHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODFzM{eg{txONg>?	NWnaRZNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjRpPkK3NFYxPzZ2PD;hQi=>
insect cell	MXfGeY5kfGmxbjDhd5NigQ>?		M2S0[VYxKG2rboO=		NVfvOWZyUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDDMZRmem2rbnHsJGhqey22YXfn[YQhUESDQ{igLFEhfG9iM{e3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJJV{cW6pIGLIT{1MMEGlKT3LLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgOlAhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjNyN{Sg{txONg>?	MnXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlQoRjJ5ME[wO\|Y1RC:jPh?=
SHSY5Y	MY\GeY5kfGmxbjDhd5NigQ>?		M372SVghcHK\|		MVrJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJHNJW1l3WTDj[YxteyC3c3nu[{BDSVSFUDDhd{B{fWK\|dILheIUh[W[2ZYKgPEBpenNiYomgWWhRVENvRWPJMW1UN02VIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wNFc5KM7:TT6=	NISwcVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[1NFkzPSd-Mke2OVA6OjV:L3G+
SHSY5Y	NEfOSYZHfW6ldHnvckBie3OjeR?=		NVv6[ppzQCCqcoO=		MYPJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gV2hUYTW\IHPlcIx{KHW\|aX7nJG1CVCCjczDzeYJ{fHKjdHWgZYZ1\XJiODDodpMh[nliVVjQUGMuTVOLLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMEmxJO69VS5?	M37RblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkWwPVI2Lz5{N{[1NFkzPTxxYU6=
Sf9	NFLQb4FHfW6ldHnvckBie3OjeR?=		MkfPOEBpenN?		NEe5eGlKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFfTWE11[WepZXSgTGRCSzFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegUW9EWEGFIHHzJJN2[nO2cnH0[UBi\nSncjC0JIhzeyCkeTDVTHBNSy2HU1mtUXMwVVNiYX7hcJl{cXNuIFnDOVAhRSByLkCxOVch\|ryPLh?=	NWKySY5lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2OVA6OjVpPkK3OlUxQTJ3PD;hQi=>
insect cell	M1vwV2Z2dmO2aX;uJIF{e2G7		NFLyTHo1KGi{cx?=		MXXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMhfXOrbnegRmFVS1BiYYOgd5Vje3S{YYTlJIFnfGW{IESgbJJ{KGK7IGXIVGxENUWVST3NV{9OWyCjbnHsfZNqeyxiSVO1NEA:KDBwMEG2JO69VS5?	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4NUC5NlUoRjJ5NkWwPVI2RC:jPh?=
SHSY5Y	MlrHSpVv[3Srb36gZZN{[Xl?		M2X5VFghcHK\|		MnjITY5pcWKrdHnvckBw\iCKRFHDNUBqdiCqdX3hckBUUFO\NWmgZ4VtdHNidYPpcochVU:FUFHDJIF{KHO3YoP0doF1\SCjZoTldkA5KGi{czDifUBWUFCOQz3FV2kuVVNxTWOgZY5idHm\|aYOsJGlEPTBiPTCwMlAyQDhizszNMi=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzZ3MEmyOUc,Ojd4NUC5NlU9N2F-
HEK293T	MXTGeY5kfGmxbjDhd5NigQ>?		NFLERmg{OCCvaX7z		M3f4e2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSFTBR\|Eh\XiycnXzd4VlKGmwIFjFT\|I6O1RiY3XscJMhfXOrbnegRYMuU0eOR1uoRYMqNU2FQTDhd{B{fWK\|dILheIUh[W[2ZYKgN\|AhdWmwczDpckBxemW\|ZX7j[UBw\iCGVGSgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yMUmg{txONg>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOU[wOEc,Ojl3MUm2NFQ9N2F-
HEK293T	M2LKdWZ2dmO2aX;uJIF{e2G7		NHvBPXo{OCCvaX7z		NES3XYhKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JI1wfXOnIFjERWM3KGW6cILld5Nm\CCrbjDISWszQTOWIHPlcIx{KGOxLXX4dJJme3OrbnegcY92e2ViSFTBNkB2e2mwZzDBZ{1MT0yJSzjBZ{kuVUODIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6\|IHnuJJBz\XOnbnPlJI9nKESWVDDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB{ODFOwG0v	M2jtTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG5OlA1Lz5{OUWxPVYxPDxxYU6=
NFF	NYXZcXp4S3m2b4TvfIlkcXS7IHHzd4F6				MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOSmYh[2WubIOsJGlEPTBiPTCwMlIh\|ryPLh?=	M2O0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkS1OFAzLz5\|MEK0OVQxOjxxYU6=
insect cell	MX7GeY5kfGmxbjDhd5NigQ>?				Mlv0TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gTGRCSzZiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBk\WyuczD1d4lv\yCUSFvLLGFkMUGPQzDhd{B{fWK\|dILheIUh[nliZnz1c5Jme2OnbnPlMYJie2WmIHHzd4F6NCCLQ{WwJF0hOC5yMEi1JO69VS5?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
Sf21	MkS3SpVv[3Srb36gZZN{[Xl?				MoLjTY5pcWKrdHnvckBw\iCFLYTldo1qdmGuIF\MRWcuUGm\|LYTh[4dm\CCodXzsJIxmdme2aDDy[YNwdWKrbnHueEBpfW2jbjDISGFEOSCneIDy[ZN{\WRiaX6gV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUljLT{hC[ymDTVOgZZMhe3Wkc4TyZZRmKGK7IH\seY9z\XOlZX7j[U1j[XOnZDDhd5NigSxiSVO1NEA:KDBwMEC5OEDPxE1w	M1PaTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
insect cell	NW\RSGI4TnWwY4Tpc44h[XO\|YYm=				M4jQbGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSFTBR\|MwVkORUkKg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCClZXzsd{B2e2mwZzDSTGtMMEGlKVHNR{BieyC\|dXLzeJJifGViYomg[ox2d3Knc3PlcoNmNWKjc3XkJIF{e2G7LDDJR\|UxKD1iMD6wNVI4KM7:TT6=	M{PLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
insect cell	MXjGeY5kfGmxbjDhd5NigQ>?				MVTJcohq[mm2aX;uJI9nKENvdHXycYlv[WxiR2PUMZRi\2enZDDy[YNwdWKrbnHueEBpfW2jbjDISGFEOiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IIXzbY5oKFKKS1uoRYMqSU2FIHHzJJN2[nO2cnH0[UBjgSCobIXvdoV{[2WwY3WtZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{Nkeg{txONg>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
insect cell	NGXPe5pHfW6ldHnvckBie3OjeR?=				NWPye\|dqUW6qaXLpeIlwdiCxZjDDMZRmem2rbnHsJGhqey22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hUESDQ{ig[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIHnud4VkfCClZXzsd{B2e2mwZzDSTGtMMEGlKVHNR{BieyC\|dXLzeJJifGViYomg[ox2d3Knc3PlcoNmNWKjc3XkJIF{e2G7LDDJR\|UxKD1iMD62NFkh\|ryPLh?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
A20	NIrUdplHfW6ldHnvckBie3OjeR?=				MkP3Rolv\GmwZzDh[oZqdmm2eTD0c5diemS\|IFjERWMyKCiKaYP0c45mKGSnYXPleJlt[XOnIEGpJIlvKG2xdYPlJGEzOCClZXzsd{wh\XiycnXzd4VlKGG\|IHLpcoRqdmdiY3;ud5RidnRiKIDLbUktKEurIE2gNE4xODFyN{Kg{txONg>?	NHzs[Go9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUm2NFQ5QSd-MUG5OlA1QDl:L3G+
Hela	Mm\DSpVv[3Srb36gZZN{[Xl?				NIDqblJKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUGWuYTDj[YxteyCwdXPs[YFzKGW6dILhZ5R{KGK7IH\seY9zcW2ndILpZ{Bie3OjeTygT4khRSByLkWwOEDPxE1w	M3XZclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUKwOVgxLz5zOUWyNFU5ODxxYU6=
Sf9	M1HQXWZ2dmO2aX;uJIF{e2G7		MU[5NEBucW6\|		MmXFTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhUESDQ{[g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|LXnu[oVkfGWmIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochWkiNSzjBZ{lCVUNiYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomg[ox2d3KrbXX0[ZItKEurIE2gNE4xODB3ODFOwG0v	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV6OUS0NUc,Ojl3OEm0OFE9N2F-
Sf21	Ml;TSpVv[3Srb36gZZN{[Xl?		M4nET\|YxKG2rboO=		NUL1cYt{UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDDMZRmem2rbnHsJGZNSUdxSHnzMZRi\2enZDDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhW2Z{MTDpcpNm[3RiY3XscJMhfXOrbnegVmhMUyiDYznBUWMh[XNic4Xid5Rz[XSnIHHmeIVzKDZyIH3pcpMh[nliZnz1c5JqdWW2ZYKsJGtqKD1iMD6wNFA3PCEQvF2u	M1rwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUi5OFQyLz5{OUW4PVQ1OTxxYU6=
insect cell	M{XVd2Z2dmO2aX;uJIF{e2G7		NXjxbIlEPjBibXnudy=>		MkOwTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDy[YNwdWKrbnHueEBpfW2jbjDDMZRmem2rbnHsJGhqey22YXfn[YQhUESDQ{OvUk11\XKvaX7hcEBIW1RvdHHn[4VlKHKnY3;tZolv[W62IHj1cYFvKE6FT2KyJEg{QTVidH:gOFg6KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IIXzbY5oKFKKS1uoRYMqSU2FIHHzJJN2[nO2cnH0[UBi\nSncjC2NEBucW6\|IHL5JIZtfW:{aX3leIVzNCCNaTC9JFAvODByOESg{txONg>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV6OUS0NUc,Ojl3OEm0OFE9N2F-
insect cell	M2LXN2Z2dmO2aX;uJIF{e2G7		NYf3ZXpPPjBibXnudy=>		NVTPUW4{UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBz\WOxbXLpcoFvfCCqdX3hckBENXSncn3pcoFtKEeVVD30ZYdo\WRiSFTBR\|Ih\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJIlve2WldDDj[YxteyC3c3nu[{BTUEuNKFHjLWFOSyCjczDzeYJ{fHKjdHWgZYZ1\XJiNkCgcYlveyCkeTDmcJVwemmvZYTldkwhU2liPTCwMlAxOzV3IN88UU4>	Ml;RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3OEm0OFEoRjJ7NUi5OFQyRC:jPh?=
insect cell	NHjOcW9HfW6ldHnvckBie3OjeR?=				M1rTPWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSFTBR\|ExKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{1qdm[nY4Tl[EBqdnOnY4SgZ4VtdHNidYPpcoch\my3b4Lv[4VvcWNicHXweIll\SCUSFvLRYMh[XNic4Xid5Rz[XSnIHL5JIZtfW:{aX3leIVzNCCNaTC9JFAvODB2N{[g{txONg>?	MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3OEm0OFEoRjJ7NUi5OFQyRC:jPh?=
insect cell	NYThNIkyTnWwY4Tpc44h[XO\|YYm=		NFT5c3Y3OCCvaX7z		MnLqTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCFLYTldo1qdmGuIFjpd{11[WepZXSgTGRCSzhiKEGgeI8hOzd5IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiaX7z[YN1KGOnbHzzJJV{cW6pIGLIT{hC[ymNKFHjLWFOSyCjczDzeYJ{fHKjdHWgZYZ1\XJiNkCgcYlveyCkeTDmcJVwemmvZYTldkwhU2liPTCwMlE1PSEQvF2u	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV6OUS0NUc,Ojl3OEm0OFE9N2F-
insect cell	M4Gy[WZ2dmO2aX;uJIF{e2G7				MUPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiSHnzMZRi\2enZDDISGFEOTFiKEGgeI8hOzR5IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiaX7z[YN1KGOnbHzzJJV{cW6pIGLIT2spSWNrQV3DJIF{KHO3YoP0doF1\SCkeTDmcJVwemmvZYTldkwhU2liPTCwMlQxOSEQvF2u	MlHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3OEm0OFEoRjJ7NUi5OFQyRC:jPh?=
GM15850	NUHMVJBxTnWwY4Tpc44h[XO\|YYm=	NF3NOYExNjFidV2=	MlT5NVIhcHK\|		MYXJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gS20yPTh3MDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB1d3SjbDDhZ4V1gWyjdHXkJIhqe3SxbnWgcIV3\WxiYYSgNE4yKHWPIHHmeIVzKDF{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MlvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MkGzOlcoRjF4OUKxN\|Y4RC:jPh?=
A549	M4fFWGZ2dmO2aX;uJIF{e2G7	M3PDNFAvOSC3TR?=			MWTJcohq[mm2aX;uJI9nKFOLUmSyJIlvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgZYJqdGm2eTD0c{BqdmS3Y3WgbJlx\XKjY3X0fYxifGmxbjDv[kB1fWK3bHnuJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczDheEAxNjFidV2=	M3rLTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUS5PFYxLz5zN{G0PVg3ODxxYU6=
ST14A	NHL3XHVHfW6ldHnvckBie3OjeR?=	MUW3OUBvVQ>?			MlO4TY5lfWO2aX;uJI9nKFKHU2SvUnJUTi2lb4XwcIVlKHKncILld5Nqd25ib3[gcJVkcW[ncnHz[UB1[WepZXSgdoF1KFKHMT;OVnNGKEKGTl[gdJJwdW:2ZYKgZYN1cX[rdImg[ZhxemW\|c3XkJIlvKFOWMUTBJINmdGy\|IHH0JFc2KG6PIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGy3Y3nm[ZJie2ViYXP0bZZqfHl?	NEjqR\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2OVk6Oyd-MUe1OlU6QTN:L3G+
HEK293	M1m5SWZ2dmO2aX;uJIF{e2G7	M3HkfVYxOCCwTR?=			NIfXNpRKdmO{ZXHz[UBqdiCJUmC3PEBxem:2ZXnuJIxmfmWuIHnuJGhGUzJ7MzDj[YxteyCjdDC2NFAhdk1iYomgbY1ufW6xYnzveC=>	NUnrSo13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OlY4OzJpPkG3OVY3PzN{PD;hQi=>
HEK293	NE[0UFBHfW6ldHnvckBie3OjeR?=	NUL3UmlvPjByIH7N			MmnFTY5kemWjc3WgbY4heHKxdHXpckBlcXO3bH\p[IUhcXOxbXXyZZNmKGyndnXsJIlvKEiHS{K5N{Bk\WyuczDheEA3ODBibl2gZpkhcW2vdX7vZoxwfA>?	M3TyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[2O\|MzLz5zN{W2Olc{OjxxYU6=
HeLa	NWjpdYh7TnWwY4Tpc44h[XO\|YYm=	NUHrN5pVOSC3TR?=	NXXQNoluOjRiaILz		Mo\tTY5lfWO2aX;uJI9nKHBzNjDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZx?=	NHTWUYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[0N\|EyOSd-MUe2OFMyOTF:L3G+
HeLa	NFjkeGJHfW6ldHnvckBie3OjeR?=	NYfWWXVWOSC3TR?=	NVnhWY42OjRiaILz		MkHPTY5lfWO2aX;uJI9nKHB{NzDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZx?=	NILRXpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[0N\|EyOSd-MUe2OFMyOTF:L3G+
HeLa	Mn7xSpVv[3Srb36gZZN{[Xl?	MX2xJJVO	Ml3LNlQhcHK\|		MmTGTY5lfWO2aX;uJI9nKHB{MTDlfJBz\XO\|aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMh[XRiMTD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZx?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ2M{GxNUc,OTd4NEOxNVE9N2F-
HCT116	NFTTUJVHfW6ldHnvckBie3OjeR?=				M17FdWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{GgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBpgXCncnHj[ZR6dGG2aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCkeTDX[ZN1\XKwIHLsc5Q>	M{njdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEW0NlM6Lz5zOEC1OFI{QTxxYU6=
HCT116	NF\DZ3VHfW6ldHnvckBie3OjeR?=				NXv0Z25oUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOkBie3Onc4Pl[EBieyC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44hcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHL5JHdme3Sncn6gZoxwfA>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB3NEKzPUc,OThyNUSyN\|k9N2F-
HEK293 STF	MkPWSpVv[3Srb36gZZN{[Xl?		M{DoVFI1KGi{cx?=		M{XrZ2FkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[EBqdiCKRVuyPVMhW1SIIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJRz[W6\|Y4LpdJRqd26jbDDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mNWKjc3XkJIxi[3SjdHWg[IVpgWS{b3flcoF{\SCjc4PhfS=>	NH3m[nE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCyNlY4PSd-MUmwNlI3PzV:L3G+
NCI-H661	NXnESoJ[TnWwY4Tpc44h[XO\|YYm=	NFTvVIM{ODBibl2=	NF[1fXo3KGi{cx?=		NW\XUFMzUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKE6FST3IOlYyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFi0JIFk\XS7bHH0bY9vKGG2IEOwNEBvVSCjZoTldkA3KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MmfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|OEW2NFAoRjF7M{i1OlAxRC:jPh?=
NCI-H661	M{\GSmZ2dmO2aX;uJIF{e2G7	MXmzNFAhdk1?	M1XWSFYhcHK\|		MnvtTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJG5EUS2KNk[xJINmdGy\|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9vKGG2IEOwNEBvVSCjZoTldkA3KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M3HlV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{i1OlAxLz5zOUO4OVYxODxxYU6=
HL60	NULxUGVbTnWwY4Tpc44h[XO\|YYm=	NVLj[206OjBidXevcYw>	MoD3NlQhcHK\|		Mmm4TY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhNPjBiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCjdDCyNEB2\y:vbDDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|NES3NUc,OTl3M{S0O\|E9N2F-
primary bronchial epithelial cell	NFTUNWJHfW6ldHnvckBie3OjeR?=	MVmwMlEhfU1?			M2naZ2lvcGmkaYTpc44hd2ZiSFTBR\|chcW5iaIXtZY4heHKrbXHyfUBjem:wY3jpZYwh\XCrdHjlcIlidCClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9vKGG2IECuNUB2VQ>?	MmLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nk[3PFkoRjF7OU[2O\|g6RC:jPh?=
MCF7	MU\GeY5kfGmxbjDhd5NigQ>?	Mnr6NE4yKHWP	M1\3fFE3KGi{cx?=		NIrxVW9KdmirYnn0bY9vKG:oIGPJVnQzKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:wIHH0JFAvOSC3TTDh[pRmeiBzNjDodpMh[nliV3XzeIVzdiCkbH;0	NInYfIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MECzNFM1Oyd-MkCwN\|A{PDN:L3G+
HeLa	NVPkUXdwTnWwY4Tpc44h[XO\|YYm=	NUnrTYFxOSC3TR?=	M1XOWlExKG2rboO=		MXrJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEGwJI1qdnNiYomg[ox2d3KxbXX0dolkKGG\|c3H5	MoDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyNUW4OFgoRjJzMEW1PFQ5RC:jPh?=
MCF7	MkPhSpVv[3Srb36gZZN{[Xl?	M1vOe\|AvPSC3TR?=	M1SxOVI1KGi{cx?=		MYXJcohq[mm2aX;uJI9nKEOuYYPzJFEhcGm\|dH;u[UBl\WGlZYT5cIF{\SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJJVxNXKnZ4XsZZRqd25ib3[gdFIyKHC{b4TlbY4hdGW4ZXygZZQhOC53IIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NUHvblR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFA{PjNpPkKyNlgxOzZ\|PD;hQi=>
MCF7	NVm5dlR{TnWwY4Tpc44h[XO\|YYm=	M1j4flAvPSC3TR?=	M{fCRVI1KGi{cx?=		NIjMTldKdmirYnn0bY9vKG:oIFjERWM3KGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4hidmenIHnuJJR2[nWuaX6gZYNmfHmuYYTpc44hdGW4ZXygZZQhOC53IIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NVfxRWh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyPFA{PjNpPkKyNlgxOzZ\|PD;hQi=>
MCF7	NFnV[2VHfW6ldHnvckBie3OjeR?=	MYewMlUhfU1?	M3\YcFI1KGi{cx?=		MYTJcohq[mm2aX;uJI9nKEiGQVOxJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNidYCtdoVofWyjdHnvckBw\iCjY3X0fYxifGWmIHjpd5RwdmViSEOgdJJwfGWrbjDs[ZZmdCCjdDCwMlUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ6MEO2N{c,OjJ{OECzOlM9N2F-
PC12	M2fucGZ2dmO2aX;uJIF{e2G7	MkXqNVAhfU1?	NFXUU5g1QCCqcoO=		NW\BUlZoUW6qaXLpeIlwdiCxZjDISGFEPiCrbjDyZZQhWENzMjDj[YxteyCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKEh\|IHH0JFExKHWPIHHmeIVzKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyNU[4NEc,OjN7MEW2PFA9N2F-
PC12	M3TXXWZ2dmO2aX;uJIF{e2G7	M13IRVExKHWP	NHXLdGI1QCCqcoO=		Mk\qTY5pcWKrdHnvckBw\iCKRFHDOkBqdiC{YYSgVGMyOiClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbjDheEAyOCC3TTDh[pRmeiB2ODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>?	MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MEW2PFAoRjJ\|OUC1OlgxRC:jPh?=
PC12	NHfyTGxHfW6ldHnvckBie3OjeR?=	MmnsNVAhfU1?	NIPKTI42KGSjeYO=		MmXsTY5lfWO2aX;uJI9nKG6ndYLpeIUhd3W2Z4Lve5RpKGmwIILheEBRSzF{IHPlcIx{KGG2IEGwJJVOKGGodHXyJFUh\GG7cx?=	M4H0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUC1OlgxLz5{M{mwOVY5ODxxYU6=
SH-SY5Y	NEfURYpHfW6ldHnvckBie3OjeR?=	NGTVbmYyOCC3TR?=	NV\MTpdkPSCmYYnz		MWDJcoR2[3Srb36gc4YhdmW3cnn0[UBwfXSpcn;3eIghcW5iaIXtZY4hW0hvU2m1XUBk\WyuczDheEAyOCC3TTDh[pRmeiB3IHThfZM>	NWThc45URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFU3QDBpPkKzPVA2PjhyPD;hQi=>
A549	MnfYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NGS0XIExNjRidV2=	MVyyOEBpenN?		M1PCdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{B{cHK3bnvlckBidmRic3jhdpAhe2ijcHWgZZQhOC52IIXNJIFnfGW{IEK0JIhzeyCkeTDwbIF{\SClb370doF{fCCvaXPyc5Nkd3C7	Mn;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OESxNVIoRjJ3OEi0NVEzRC:jPh?=
HeLa	NFnTNnVHfW6ldHnvckBie3OjeR?=				M2HqSmlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5iaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczD0eYJ2dGmwIHHj[ZR6dGG2aX;uJIlv[3WkYYTl[EBnd3Jib4\ldo5q\2i2IHL5JIludXWwb3\seY9z\XOlZX7j[UBucWO{b4Pjc5Bq[yCjbnHsfZNqew>?	NXPv[GliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2NVE6OTlpPkK2OlEyQTF7PD;hQi=>
C127-LT	NHXy[IpHfW6ldHnvckBie3OjeR?=	M4j6WlIxOCCwTR?=	MV6yOEBpenN?		MW\Jcohq[mm2aX;uJI9nKEiGQVOgbY4hdW:3c3WgR\|EzPy2OVDDj[YxteyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKEWJRmCg[ZhxemW\|c3nvckBifCB{MECgcm0h[W[2ZYKgNlQhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7	NYrTbFVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVY{PzJpPkK2PVk3Ozd{PD;hQi=>
HeLa nuclear	MXvGeY5kfGmxbjDhd5NigQ>?	NGHqdogyOCC2bzCyOUB2VQ>?	NFfPVo8{OCCvaX7z		M3nNb2NwdXCndHn0bZZmKGmwaHnibZRqd25ib3[gTGRCSyCrbjDoeY1idiCKZVzhJI52[2ynYYKgZ4VtdHNiYYSgNVAhfG9iMkWgeW0hfXOrbnegRo9kNWGlZYT5cE1tgXOrbnWtRW1EKGG\|IIP1ZpN1emG2ZTDh[pRmeiB\|MDDtbY5{KGK7IFzpcoV4\WG4ZYKtRpVzcyCybH;0JIFv[Wy7c3nz	Mki4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OU[zO\|IoRjJ4OUm2N\|czRC:jPh?=
HeLa	M4X1V2Z2dmO2aX;uJIF{e2G7	MlT1NkB2VQ>?	M2PT[FI1KGi{cx?=		MXLJcohq[mm2aX;uJI9nKEiGQVOxJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaInw[ZJi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KDJidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NGrGb4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3PCd-MkewOlA4PjR:L3G+
HN13	M2DycGZ2dmO2aX;uJIF{e2G7		NVvUO5NOOjRiaILz		M3W5XGlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBJVjF\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBpcXO2b37lJGg{KEy7c{mgZYNmfHmuYYTpc44hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgbY1ufW6xZnz1c5Jme2OnbnPlJIF{e2G7	M{X6N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEOxNFY3Lz5{OUCzNVA3PjxxYU6=
HeLaS3	MVzGeY5kfGmxbjDhd5NigQ>?	M3vYelExKHWP			MmXSTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhmVGGVMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{UzliYXPleJlt[XSrb36gZZQhOTBidV2gcYVie3W{ZXSgbY1u\WSrYYTlcJkh[nliaX3teY5w[myxdDDhcoFtgXOrcx?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ3OEWzOUc,OzB{NUi1N\|U9N2F-
HeLaS3	MnTjSpVv[3Srb36gZZN{[Xl?	NHi3[HkyOCC3TR?=	MX:xOkBpenN?		MUnJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTIVN[VN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFNMQSCjY3X0fYxifGmxbjDheEAyOCC3TTD0doVifGWmIH\vdkAyPiCqcoOg[o9tdG:5ZXSgZpkh[2:vcH;1coQhf2G\|aH;1eEBidmRibXXhd5Vz\WRidYCgeI8hOjRiaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	M2nnOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkW4OVM2Lz5\|MEK1PFU{PTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / STAT3 ; PubMed: 31289542 Oncol Lett Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting. Cyclin D1 / CDK6 / CDK4 / p-RB / RB; PubMed: 31289542 Oncol Lett Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. MMP-1 / MMP-3 / MMP-13 / TIMP-1; PubMed: 27431944 Mol Med Rep Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h. Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); PubMed: 27431944 Mol Med Rep Chondrocytes were treated with increasing concentrations of TSA for 24 h. α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; PubMed: 23802098 Front Oncol Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).	31289542 27431944 23802098
Immunofluorescence	α-C/EBPβ / α-HP1α ; PubMed: 21122806 Exp Cell Res 3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. α-HDAC1 ; PubMed: 29045501 PLoS One MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels. α-tubulin / acetylated histone 3; PubMed: 27957719 Neurotherapeutics Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.	21122806 29045501 27957719
Growth inhibition assay	Cell viability (A549 cells); PubMed: 27571418 PLoS One Cytotoxicity of histamine determined by MTT assay in A549 cells. Cell viability (MDA-MB-231 cells); PubMed: 27548148 Int J Mol Sci The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8. Cell viability (PC3 cells); PubMed: 31289542 Oncol Lett PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.	27571418 27548148 31289542

In vivo

Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. ^[1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro HDAC activity: Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×10⁵ cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 10⁶ cpm) of [³H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [³H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [³H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research: ^[1]	- Collapse Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM Incubation Time: 96 hours Method: Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU Dosages: ~5 mg/kg/day Administration: Injection s.c. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	23 mg/mL (76.05 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	1.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Trichostatin A (TSA) SDF

Molecular Weight	302.4
Formula	C₁₇H₂₂N₂O₃
CAS No.	58880-19-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03887650	Unknown status	Drug: Liposomal Bupivicaine 1.3%\|Drug: Bupivacaine 0.5%	Post-operative Pain\|Total Shoulder Arthroplasty\|Osteoarthritis of the Shoulder\|Pain Management	Hartford Hospital	January 14 2019	Phase 4
NCT03838926	Unknown status	Drug: Trichostatin A	Relapsed or Refractory Hematologic Malignancies	Vanda Pharmaceuticals	September 27 2018	Phase 1
NCT02976272	Unknown status	Other: bortezomib	Multiple Myeloma\|Bortezomib Regimen\|Adult	University Hospital Clermont-Ferrand\|Laboratoires Takeda	June 7 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?
Answer:
Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Trichostatin A (TSA)